NeoImmuneTech, Inc.
A clinical-stage biopharma developing T cell-focused immuno-therapeutics for diseases.
950220 | KO
Overview
Corporate Details
- ISIN(s):
- KR8840140006
- LEI:
- Country:
- United States of America
- Address:
- 2400 Research Boulevard, Suite 250, Rockville, MD 20850, Rockville
- Website:
- https://www.neoimmunetech.com/en
Description
NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-30 00:00 |
증권신고서(증권예탁증권)
|
Korean | 2.2 MB | ||
| 2025-05-20 00:00 |
기업설명회(IR)개최
|
Korean | 7.2 KB | ||
| 2025-05-19 00:00 |
투자판단관련주요경영사항(임상시험결과) (NIT112 (거대 B세포 림프종, NTI7 및 CART 치료제 병용 요법) 임…
|
Korean | 22.2 KB | ||
| 2025-05-15 00:00 |
분기보고서 (2025.03)
|
Korean | 1.2 MB | ||
| 2025-04-30 00:00 |
전환가액의조정 (제1회차)
|
Korean | 11.3 KB | ||
| 2025-04-03 00:00 |
기업설명회(IR)개최
|
Korean | 7.3 KB | ||
| 2025-03-31 00:00 |
정기주주총회결과
|
Korean | 20.0 KB | ||
| 2025-03-26 00:00 |
기업설명회(IR)개최
|
Korean | 7.3 KB | ||
| 2025-03-21 00:00 |
사업보고서 (2024.12)
|
Korean | 1.6 MB | ||
| 2025-03-20 00:00 |
감사보고서제출
|
Korean | 28.3 KB | ||
| 2025-03-14 00:00 |
주주총회소집결의
|
Korean | 9.6 KB | ||
| 2025-03-14 00:00 |
주주총회소집공고
|
Korean | 108.9 KB | ||
| 2025-03-14 00:00 |
의결권대리행사권유참고서류
|
Korean | 99.2 KB | ||
| 2025-02-14 00:00 |
매출액또는손익구조30%(대규모법인은15%)미만변동(자율공시)
|
Korean | 12.5 KB | ||
| 2025-01-10 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.7 KB |
Automate Your Workflow. Get a real-time feed of all NeoImmuneTech, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NeoImmuneTech, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NeoImmuneTech, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
